Showing results (151-160 of 216) with videos related to

Sort By:
Pageof 22
The Journal of Antibiotics|July 1, 1977
BL-S786, a new parenteral cephalosporin. II. In vitro antimicrobial activity comparison with six related cephalosporinsR N Jones, C Thornsberry, A L Barry, et al.
Antimicrobial Agents and Chemotherapy|December 1, 1981
Cefmenoxime (SCE-1365), a new cephalosporin: in vitro activity, comparison with other antimicrobial agents, beta-lactamase stability, and disk diffusion testing with tentative interpretive criteriaP C Fuchs, R N Jones, C Thornsberry, et al.
Journal of Clinical Microbiology|January 1, 1989
Quality control limits for the standard anaerobic reference agar dilution susceptibility test procedure of the National Committee for Clinical Laboratory StandardsA L Barry, P C Fuchs, S D Allen, et al.
Burns : Journal of the International Society for Burn Injuries|February 25, 2022
The BUrn Mortality Prediction (BUMP) Score - An improved mortality prediction score based on data of the German burn registryM Bagheri, P C Fuchs, R Lefering, et al.
The Journal of Antimicrobial Chemotherapy|January 1, 1996
Tentative interpretive criteria and quality control parameters for in-vitro susceptibility testing of Neisseria gonorrhoeae to two fluoroquinolones (PD 131628 and grepafloxacin (OPC 17116))D L Sewell, A L Barry, S D Allen, et al.
Antimicrobial Agents and Chemotherapy|April 1, 1980
Moxalactam (LY127935), a new semisynthetic 1-oxa-beta-lactam antibiotic with remarkable antimicrobial activity: in vitro comparison with cefamandole and tobramycinR N Jones, P C Fuchs, H M Sommers, et al.
Diagnostic Microbiology and Infectious Disease|July 1, 1991
Antimicrobial activity of cefpirome. An update compared to five third-generation cephalosporins against nearly 6000 recent clinical isolates from five medical centersR N Jones, M A Pfaller, S D Allen, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|August 1, 1992
Comparison of fixed concentration and fixed ratio options for testing susceptibility of gram-negative bacilli to piperacillin and piperacillin/tazobactamM A Pfaller, A L Barry, P C Fuchs, et al.
Diagnostic Microbiology and Infectious Disease|November 1, 1986
In vitro activity of carumonam (RO 17-2301), BMY-28142, aztreonam, and ceftazidime against 7,620 consecutive clinical bacterial isolatesP C Fuchs, R N Jones, A L Barry, et al.
The Journal of Antimicrobial Chemotherapy|February 1, 1996
In-vitro susceptibility of Streptococcus pneumoniae to the d- and l-isomers of ofloxacin: interpretive criteria and quality control limitsA L Barry, P C Fuchs, S D Allen, et al.
Pageof 22